Home > Healthcare > Pharmaceuticals > Finished Drug Form > Scopolamine Market

Scopolamine Market Trends

Report ID: GMI9743
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Scopolamine Market Trends

Advancements in novel drug delivery systems have significantly improved the accessibility and administration of scopolamine, enhancing its efficacy and patient compliance. The development of scopolamine transdermal drug delivery systems, which is estimated to reach USD 61 billion by 2032, enables continuous drug delivery over typically three days, offering a more convenient option for patients compared to oral or injectable forms.
Additionally, pharmaceutical advancements have facilitated the creation of sustained-release formulations, ensuring steady drug levels in the body and prolonged therapeutic effects.
Therefore, these innovations collectively contribute to the improved delivery and performance of scopolamine, making it a more reliable option for patients in need of antiemetic treatment.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Scopolamine industry size was USD 419 million in 2023 and will grow at 5.3% CAGR between 2024 and 2032 due to its extensive application in the pharmaceutical sector for treating motion sickness, nausea, and vomiting.

The motion sickness segment in the scopolamine industry recorded USD 203.9 million in 2023, driven by rising prevalence of motion sickness due to increased travel and transportation activities.

North America scopolamine industry will register USD 241.3 million by 2032, attributed to region's advanced healthcare infrastructure, coupled with high healthcare spending.

Alchem International Pvt. Ltd., Australian Alkaloids Ltd., Baxter International Inc., Caleb Pharmaceuticals, Inc., Fine Chemicals Corporation, Fresenius SE & Co. KGaA, GSK plc, Ingenus Pharmaceuticals, and Mylan N.V. among others.